Skip to main content
Department of Health Department of Health An Roinn Sláinte Männystrie O Pouste

Main navigation

  • Home
  • Topics
  • Publications
  • Consultations
  • Contact

Translation help

Translate this page

Select a language

  • Arabic — عربي
  • Chinese (Simplified) — 中文简体
  • Chinese (Traditional) — 中文繁體
  • Dutch — Nederlands
  • Filipino — Filipino
  • French — Français
  • German — Deutsch
  • Hungarian — Magyar
  • Irish — Gaeilge
  • Italian — Italiano
  • Latvian — Latviešu
  • Lithuanian — Lietuvių kalba
  • Polish — Polski
  • Portuguese — Português
  • Romanian — Română
  • Russian — Русский
  • Slovak — Slovenčina
  • Spanish — Español
  • Ukrainian — Українська
  • NICE - Endorsed Technology Appraisals 2020/2021

    Topics:
    • Safety and quality, 
    • NICE technology appraisals

    It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

    Technology Appraisals Endorsement Process

    The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;

    NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.

    For information, details of the previous arrangement can be found on the following circular;

    NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11

    2020/2021

    The following technology appraisals have been endorsed during 2020/21. Information on technology appraisals endorsed in previous years can be found on the homepage.

    March 2021

    TA681 - Baricitinib for treating moderate to severe atopic dermatitis

    TA680 - Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma

    TA679 - Dapagliflozin for treating chronic heart failure with reduced ejection fraction

    TA677 - Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma

    TA676 - Filgotinib for treating moderate to severe rheumatoid arthritis

    TA673 - Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

    TA672 - Brolucizumab for treating wet age-related macular degeneration

    TA671 - Mepolizumab for treating severe eosinophilic asthma Note this guidance updates and replaces NICE Technology Appraisal TA431, which was endorsed by the DoH in February 2017.

    February 2021

    TA670 - Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor

    TA669 - Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies

    ‘Note this guidance has been updated and replaced by TA852 - Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments, which was endorsed by the DoH in January 2023.’

    TA668 - Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer

    January 2021

    TA667 - Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura

    TA666 - Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma

    TA665 - Upadacitinib for treating severe rheumatoid arthritis

    TA664 - Liraglutide for managing overweight and obesity

    TA663 - Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia

    December 2020

    TA661 - Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma

    TA660 - Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer

    TA659 - Galcanezumab for preventing migraine

    TA658 - Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma

    TA657 - Carfilzomib for previously treated multiple myeloma Note this guidance has been partially updated and replaced by TA695 - Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma, which was endorsed by the DoH in May 2021

    TA656 - Siponimod for treating secondary progressive multiple sclerosis

    November 2020

    TA655 - Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy Note this guidance updates and replaces NICE Technology Appraisal TA483, which was endorsed by the DoH in January 2019.

    TA654 - Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer

    TA653 - Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer

    October 2020

    TA651 - Naldemedine for treating opioid-induced constipation

    TA650 - Pembrolizumab with axitinib for untreated advanced renal cell carcinoma

    TA649 - Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma

    September 2020

    TA645 - Avelumab with axitinib for untreated advanced renal cell carcinoma

    TA644 - Entrectinib for treating NTRK fusion-positive solid tumours

    TA643 - Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer

    TA642 - Gilteritinib for treating relapsed or refractory acute myeloid leukaemia

    TA641 - Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma

    TA640 - Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant

    August 2020

    TA639 - Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer

    TA638 - Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer

    July 2020

    TA633 - Ustekinumab for treating moderately to severely active ulcerative colitis

    TA632 - Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer

    TA631 - Fremanezumab for preventing migraine

    ‘Note this guidance has been updated and replaced by TA764 - Fremanezumab for preventing migraine, which was endorsed by the DoH in February 2022’.

    TA630 - Larotrectinib for treating NTRK fusion-positive solid tumours

    NICE TA629 - Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab Note this guidance updates and replaces NICE Technology Appraisal TA472, which was endorsed by the DoH in January 2019.

    NICE TA628 - Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer

    NICE TA627 - Lenalidomide with rituximab for previously treated follicular lymphoma

    NICE TA626 - Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure

    Related content

    • NICE - Endorsed Technology Appraisals 2006/2007
    • NICE - Endorsed Technology Appraisals 2007/2008
    • NICE - Endorsed Technology Appraisals 2008/2009
    • NICE - Endorsed Technology Appraisals 2009/2010
    • NICE - Endorsed Technology Appraisals 2010/2011
    • NICE - Endorsed Technology Appraisals 2011/2012
    • NICE - Endorsed Technology Appraisals 2012/2013
    • NICE - Endorsed Technology Appraisals 2013/2014
    • NICE - Endorsed Technology Appraisals 2014/2015
    • NICE - Endorsed Technology Appraisals 2015/2016
    • NICE - Endorsed Technology Appraisals 2016/2017
    • NICE - Endorsed Technology Appraisals 2017/2018
    • NICE - Endorsed Technology Appraisals 2018/2019
    • NICE - Endorsed Technology Appraisals 2019/2020
    • NICE - Endorsed Technology Appraisals 2021/2022
    • NICE - Endorsed Technology Appraisals 2022/2023
    • NICE - Endorsed Technology Appraisals 2023/2024
    • NICE - Endorsed Technology Appraisals 2024/2025
    • NICE Technology Appraisals
    Share this page Share on Facebook (external link opens in a new window / tab) Share on X (external link opens in a new window / tab) Share by email (external link opens in a new window / tab)

    Department footer links

    • Crown copyright
    • Terms and Conditions
    • Privacy
    • Cookies
    • Accessibility
    • The Northern Ireland Executive
    • The Executive Office
    • Department of Agriculture, Environment and Rural Affairs
    • Department for Communities
    • Department for Education
    • Department for the Economy
    • Department of Finance
    • Department for Infrastructure
    • Department for Health
    • Department of Justice
    • nidirect.gov.uk — the official government website for Northern Ireland citizens